Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Paraganglioma × NET × Clear all

Phase

Phase 2 8 Phase 1/2 4 Phase 1 3 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 8 Somatostatinoma 2 Gastroenteropancreatic Neuroendocrine Tumors 2 Adenoma, Islet Cell 2 Vipoma 1 Pheochromocytoma 1 Paraganglioma 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Insulinoma 1 Glucagonoma 1 Gastrinoma 1 Carcinoma, Islet Cell 1 Carcinoid Tumor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00442533 2023-04-03

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Radio Isotope Therapy of America

Phase 2/3 Completed

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡